Table 1. Laboratory-confirmed infant botulism cases by serotype and province/territory, 1979–2019.
| Province/territory | Cases by BoNT serotype | Total | Annual rate/million live birthsa | |||
|---|---|---|---|---|---|---|
| A | B | AB | F | |||
| Ontario | 11 | 9 | 1 | 0 | 21 | 3.75 |
| British Columbia | 19 | 0 | 0 | 0 | 19 | 10.86 |
| Québec | 9 | 2 | 0 | 1 | 12 | 3.63 |
| Alberta | 8 | 0 | 0 | 0 | 8 | 4.41 |
| Newfoundland and Labrador | 1 | 1 | 0 | 0 | 2 | 9.93 |
| Nova Scotia | 0 | 1 | 0 | 0 | 1 | 2.66 |
| Canadab | 48 | 13 | 1 | 1 | 63 | 4.30 |
Abbreviation: BoNT, botulinum neurotoxin
a Annual rate per million live births was calculated as the total case count divided by the average number of annual live births from 1991–2018 multiplied by 40 (years), divided by a million (21,22)
b No laboratory-confirmed cases of infant botulism in Manitoba, New Brunswick, Northwest Territories, Nunavut, Prince Edward Island, Saskatchewan or Yukon